(NASDAQ: KYNB) Kyntra Bio's forecast annual earnings growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast earnings growth rate of 24.9%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 69.05%.
Kyntra Bio's earnings in 2026 is $163,615,000.On average, 5 Wall Street analysts forecast KYNB's earnings for 2026 to be -$56,767,889, with the lowest KYNB earnings forecast at -$60,975,092, and the highest KYNB earnings forecast at -$52,748,923. On average, 5 Wall Street analysts forecast KYNB's earnings for 2027 to be -$47,222,846, with the lowest KYNB earnings forecast at -$58,912,174, and the highest KYNB earnings forecast at -$32,176,418.
In 2028, KYNB is forecast to generate -$50,227,354 in earnings, with the lowest earnings forecast at -$71,103,063 and the highest earnings forecast at -$29,371,077.